Trerief tablets 50 mg for Parkinson’s disease (zonisamide)

General information on Japanese Trerief tablets 50 mg for Parkinson’s disease (zonisamide)

Package details: 30 tablets

Manufacturer: Sumitomo Dainippon Pharma Co.,Ltd., Japan

Active ingredient: zonisamide (chemical formula C8H8N2O3S)

Medical effect: Trerief tablets are effective for the treatment of Parkinson’s disease.

Contraindications and precautions: do not use in pregnant and breastfeeding women.

As this medicine may cause drowsiness or lack of concentration, avoid working with dangerous mechanisms or driving a car while taking this medicine. If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Trerief tablets 50 mg from Japan for Parkinson’s disease (zonisamide)

For adults, take 0.5 tablet (25 mg of the active ingredient) once a day, concomitantly with levodopa-containing products. For improvement of circadian change of symptoms in Parkinson's disease, take 1 tablet (50 mg) once a day, concomitantly with levodopa-containing products.

The medicine can be taken with or without water. If you use it without water, moisten the tablet with saliva on the tongue and crush it lightly with the tongue, then swallow it with saliva.

How effective are Japanese Trerief tablets 50 mg for Parkinson’s disease (zonisamide)?

Trerief tablets contain zonisamide, a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. They provide the following effects:

1. elevate the dopamine level,
2. enhance and prolong antiparkinsonian effect of levodopa,
3. improves motor symptoms,
4. improve the circadian change of symptoms (wearing-off phenomenon).

Who should take Trerief tablets 50 mg from Japan?

Zonisamide was primarily used as an anticonvulsant for patient with epilepsy. Later, this medicine was found to improve the symptoms of Parkinson’s disease in patients who had both epilepsy and Parkinson’s disease. Currently, Trerief tablets have been studied in clinical trials and approved in Japan for the treatment of the motor symptoms of Parkinson's disease, as an adjunct to levodopa. Studies showed that zonisamide allows to decrease the amount of levodopa, induce quinone formation and protection against mitochondrial impairment, increase astroglial cysteine transport, inhibit the microglial activation and monoamine oxidase-B (MAO-B), increase dopamine release and block the calcium channels (N. D. Grover, R. P. Limaye et al. "Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease". Indian Journal of Pharmacology, 2013, 45 (6): 547–55).